Related Experiment Videos

[Therapy of diabetic retinopathy with somatostatin analogues]

G E Lang1

  • 1Universitäts-Augenklinik, Ulm.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|March 10, 2004
PubMed

Insights

Somatostatin analogues like octreotide show promise for treating diabetic retinopathy by blocking growth hormone and IGF-1. Clinical evidence suggests octreotide can slow or reverse this serious eye condition.

Area of Science:

  • Endocrinology
  • Ophthalmology
  • Vascular Biology

Background:

  • Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are implicated in diabetic retinopathy pathogenesis.
  • Somatostatin receptors are present in the retina, suggesting a therapeutic target.
  • Diabetic retinopathy is a leading cause of vision loss, necessitating effective treatments.

Purpose of the Study:

  • To evaluate the efficacy of somatostatin analogues, specifically octreotide, in treating diabetic retinopathy.
  • To investigate the mechanism of action of octreotide in inhibiting angiogenic effects related to GH and IGF-1.

Main Methods:

  • Review of evidence from animal models of diabetic retinopathy.
  • Analysis of clinical trial data in patients with advanced diabetic retinopathy and diabetic macular edema.

Main Results:

  • Octreotide demonstrated safety and effectiveness in treating advanced diabetic retinopathy and diabetic macular edema.
  • The compound successfully blocked local and systemic production of GH and IGF-1, inhibiting angiogenesis.
  • Evidence suggests octreotide can delay disease progression and partially reverse existing diabetic retinopathy.

Conclusions:

  • Somatostatin analogues, exemplified by octreotide, represent a viable therapeutic strategy for diabetic retinopathy.
  • Octreotide's mechanism involves suppressing GH and IGF-1, thereby mitigating retinal vascular disease.
  • Further research supports octreotide as a treatment to manage and potentially improve outcomes in diabetic retinopathy.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...